RxDoctor Payments Data

Jorge Figueroa, MD

Family Medicine · Largo, FLNPI 1225100803

Payments from drug & device makers

$1,277in general payments, 2019–2025

Across 49 payments — averaging $26.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$566
  • Boehringer Ingelheim$250
  • Lilly USA, LLC$172
  • AstraZeneca$134
  • Bayer$88
  • Sunovion Pharmaceuticals Inc.$29
  • plus $39 from 3 others

What the payments were for

  • Food & beverage$1,277100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,277 in reported general payments places this provider in the 65th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$3,536
Medicare patients
12
Services billed
64

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide66$64,808
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$63,756
EliquisApixaban41$57,130
BiktarvyBictegrav/Emtricit/Tenofov Ala11$41,166
XareltoRivaroxaban32$38,699
FarxigaDapagliflozin Propanediol37$36,015
JardianceEmpagliflozin23$34,499
OzempicSemaglutide33$31,041
Celecoxib158$25,286
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$21,760
Gabapentin468$18,742
Nebivolol Hcl170$16,977
Duloxetine Hcl261$15,905
Xultophy 100-3.6Insulin Degludec/Liraglutide12$15,635
MyrbetriqMirabegron25$13,860

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$134$65,65785 claims
Lilly USA, LLCTrulicity$172$64,80866 claims
GSKTrelegy Ellipta$566$63,75654 claims
Novo NordiskOzempic, Xultophy 100-3.6$12$46,67645 claims
Boehringer IngelheimJardiance$250$34,49923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Largo

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →